2E40 Stock Overview
A biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
PHAXIAM Therapeutics S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.49 |
| 52 Week High | €4.85 |
| 52 Week Low | €1.45 |
| Beta | 1.82 |
| 11 Month Change | -4.97% |
| 3 Month Change | -5.70% |
| 1 Year Change | -64.44% |
| 33 Year Change | -93.44% |
| 5 Year Change | -96.42% |
| Change since IPO | -99.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2E40 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.1% | 1.3% |
| 1Y | -64.4% | -18.5% | 7.9% |
Return vs Industry: 2E40 underperformed the German Biotechs industry which returned -18.5% over the past year.
Return vs Market: 2E40 underperformed the German Market which returned 7.9% over the past year.
Price Volatility
| 2E40 volatility | |
|---|---|
| 2E40 Average Weekly Movement | 11.8% |
| Biotechs Industry Average Movement | 6.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2E40's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2E40's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 68 | Thibaut Fayet | www.phaxiam.com |
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa.
PHAXIAM Therapeutics S.A. Fundamentals Summary
| 2E40 fundamental statistics | |
|---|---|
| Market cap | €15.92m |
| Earnings (TTM) | -€21.92m |
| Revenue (TTM) | €2.14m |
7.4x
P/S Ratio-0.7x
P/E RatioIs 2E40 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2E40 income statement (TTM) | |
|---|---|
| Revenue | €2.14m |
| Cost of Revenue | €0 |
| Gross Profit | €2.14m |
| Other Expenses | €24.06m |
| Earnings | -€21.92m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.19 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,023.91% |
| Debt/Equity Ratio | 51.8% |
How did 2E40 perform over the long term?
See historical performance and comparison